Ixazomib- versus bortezomib-based proteasome inhibitor triplet regimens in older transplant-ineligible newly diagnosed multiple myeloma: A scoping review of real-world evidence

Keywords

Additional keywords may be available in the full-text protocol.

Registration timing

Retrospective

Review stage at registration

Formal screening of search results against eligibility criteria

Current review stage

Ongoing